PCSK9 Inhibitors: The Role of the Pharmacist in Identifying and Addressing the Clinical and Economic Barriers for the Treatment of Hyperlipidemia
Regeneron Pharmaceuticals, Inc.
Faculty
Paul B. Shaw, PharmD, BCPS, BCCP
Clinical Pharmacy Specialist – Cardiology
Kaiser Permanente of Colorado
Clinical Assistant Professor – University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Lafayette, Colorado
Medical Writer of Patient Counseling Video Vignettes
Deep Patel, PharmD, MBA
Clinical Coordinator, Transitions of Care
Department of Pharmacy
Long Island Jewish Medical Center
New Hyde Park, New York
PCSK9 Inhibitors | Pharmacy Connect Podcast
Program Description
Hyperlipidemia affects nearly 93 million Americans older than 20 years of age and is a major contributing factor to development of atherosclerotic cardiovascular disease (ASCVD). Statin therapy has widely been used for lipid-lowering therapy, but is not an option for many patients and has its own set of barriers. The rise of PCSK9 inhibitors has offered patients and clinicians another option for treatment of hyperlipidemia. Real-world data associated with PCSK9 inhibitors have shown beneficial results, and organizations have adopted them into management guidelines. Pharmacists are instrumental in providing prescribers and patients with this pertinent information to encourage their adoption. An important step for pharmacists is identifying patients who may be appropriate candidates for PCSK9 inhibitors and clinical counseling videos embedded in this activity model recognition of patient factors for treatment through motivational interviewing techniques. Specific counseling pearls revolving around PCSK9 inhibitor treatment options that pharmacists can use with prescribers and patients will also be reviewed in this activity.
Please click here to view a pharmacist identifying an appropriate candidate for a PCSK9 inhibitor and educating the patient on important counseling tips when starting a PCSK9 inhibitor.
Target Audience: Retail pharmacists
Type of Activity: Application
Release date: December 18, 2020
Expiration date: July 18, 2022
Time to complete activity: 2.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathogenesis, incidence, risk factors, and current standards of care for the treatment of hyperlipidemia
- Explore the efficacy and safety data associated with the use of PCSK9 inhibitors and their clinical benefits in the treatment of hyperlipidemia
- Discuss the current hyperlipidemia management guidelines from the American Heart Association and the American College of Cardiology
- Identify the role of the pharmacist in patient education and recognizing and educating patients who may be ideal candidates or currently on PCSK9 inhibitors for the treatment of hyperlipidemia through motivational interviewing
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.5 contact hours (0.25 CEU) under the ACPE universal activity number 0290-0000-20-383-H01-P. The activity is available for CE credit through July 18, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Paul B. Shaw, PharmD, BCPS, BCCP
Medical Writer of Patient Counseling Video Vignettes
Deep Patel, PharmD, MBA
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
